February 16, 2021 -- Contract research organization Avance Biosciences is expanding its Houston facility to meet growing demand for cell-based manufacturing.
The new facility is located adjacent to the company's existing facility and is expected to be completed in the third quarter of 2021. The additional 5,500 sq ft will be devoted to cell-based assay services and enable Avance to better address client needs related to good manufacturing practices.
Additionally, the company is expanding its mammalian cell culture-related assay capabilities, including mycoplasma testing, adventitious agents testing, sterility, and potency.
In 2020, Avance added 7,500 sq ft dedicated to next-generation sequencing and droplet digital polymerase chain reaction (PCR) capabilities to support edited gene testing, gene integration assays, and DNA/RNA biodistribution studies for gene therapy clients.
Copyright © 2021 scienceboard.net